Interferon-γ inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway

Journal of Endocrinology

Volumn 199, Issue 2, 2008, Pages 177-189

  Labeur, Marta ^a   Refojo, Damian ^a   Wölfel, Barbara ^a   Stalla, Johanna ^a   Vargas, Vivian ^a   Theodoropoulou, Marily ^a   Buchfelder, Michael ^b   Paez Pereda, Marcelo ^c   Arzt, Eduardo ^d   Stalla, Günter K ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Affectis Pharmaceutical AG   (Germany)

^d INSTITUTO DE FISIOLOGÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 1; GAMMA INTERFERON RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; PROOPIOMELANOCORTIN; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ACTH SECRETING ADENOMA; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CUSHING DISEASE; GENE EXPRESSION REGULATION; GENE REPRESSION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; HUMANS; INTERFERON-GAMMA; JANUS KINASES; MICE; NF-KAPPA B; PITUITARY NEOPLASMS; PRO-OPIOMELANOCORTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 56849116562     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-08-0011     Document Type: Article

References (72)

1. Aaronson DS & Horvath CM 2002 A road map for those who don't know JAK-STAT. Science 296 1653-1655.
2. Aguet M, Dembic Z & Merlin G 1988 Molecular cloning and expression of the human interferon-gamma receptor. Cell 55 273-280.
3. Arzt E 2001 gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways. Journal of Clinical Investigation 108 1729-1733.
4. Auernhammer CJ & Melmed S 2000 Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocrine Reviews 21 313-345.
5. Auernhammer CJ, Chesnokova V, Bousquet C & Melmed S 1998 Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Molecular Endocrinology 12 954-961.
6. Belardelli F 1995 Role of interferons and other cytokines in the regulation of the immune response. Acta Pathologica, Microbiologica. et Immunologica Scandinavica 103 161-179.
7. Besedovsky HO & del Rey A 1996 Immune-neuro-endocrine interactions: facts and hypotheses. Endocrine Reviews 17 64-102.
8. Billiau A 1996 Interferon-gamma: biology and role in pathogenesis. Advances in Immunology 62 61-130.
9. Boehm U, Klamp T, Groot M & Howard JC 1997 Cellular responses to interferon-gamma. Annual Review of Immunology 15 749-795.
10. Bousquet C & Melmed S 1999 Critical role for STAT3 in murine pituitary adrenocorticotropin hormone leukemia inhibitory factor signaling. Journal of Biological Chemistry 274 10723-10730.
11. Bousquet C, Zatelli MC & Melmed S 2000 Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immunoneurciendocrine interfacing. Journal of Clinical Investigation 106 1417-1425.
12. Boutillier AL, Monnier D, Lorang D, Lundblad JR, Roberts JL & Loeffler JP 1995 Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. Molecular Endocrinology 9 745-755.
13. Boutillier AL, Gaiddon C, Lorang D, Roberts JL & Loeffler JP 1998 Transcriptional activation of the proopiomelanocortin gene by cyclic AMP-responsive element binding protein. Pituitary 1 33-43.
14. Bromberg J 2002 Star proteins and oncogenesis. Journal of Clinical Investigation 109 1139-1142.
15. Bromberg JF, Horvath CM, Wen Z, Schreiber RD & Darnell JE Jr 1996 Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon ganum. PNAS 93 7673-7678.
16. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C & Darnell JE Jr 1999 Stat3 as an oncogene. Cell 98 295-303.
17. Buszello H 1995 Antiproliferative effects of four diferent cytokines on renal carcinoma cell lines. Anticancer Research 15 735-738.
18. Calo V, Mighavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N & Russo A 2003 STAT proteins: from normal control of cellular events to tumorigenesis. Journal of Cellular Physiology 197 157-168.
19. Chew LJ, King WC, Kennedy A & Gallo V 2005 Interferon-gamma inhibits cell cycle exit in differentiating oligodendrocyte progenitor cells. Glia 52 127-143.
20. Chin YE, Kitagawa. M, Su WC, You ZH, Iwamoto Y & Fu XY 1996 Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272 719-722.
21. Darnell JE Jr 1997 STATs and gene regulation. Science 277 1630-1635.
22. Deb A, Haque SJ, Mogensen T, Silverman RH & Williams BR 2001 RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. Journal of Immunology 166 6170-6180.
23. Gagner JP & Drouin J 1987 Tissue-specific regulation of pituitary proopiomelanocortin gene transcription by corticotropin-releasing hormone, 3′,5′-cyclic adenosine monophosphate, and glucocorticoids. Molecular Endocrinology 1 677-682.
24. Ganster KW, Guo Z, Shao L & Geller DA 2005 Differential effects of TNF-alpha and IFN-gamma on gene transcription mediated by NF-kappaB-Stat1 interactions. Journal of Interferon & Cytokine Research 25 707-719.
25. Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M et al. 2006 Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147 247-256.
26. Gutierrez H, Hale VA, Dolcet X & Davies A 2005 NF-kappaB signalling regulates the growth of neural processes in the developing PNS and CNS. Development 132 1713-1726.
27. Harvat BL, Seth P & Jetten AM 1997 The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene 14 2111-2122.
28. Hemmi S, Bohni R, Stark G, Di Marco F & Aguet M 1994 A novel member of the interferon receptor family complements functionality of the murine interferon gamma receptor in human cells. Cell 76 803-810.
29. Holsboer F, Stalla GK, von Bardeleben U, Hammann K, Muller H & Muller OA 1988 Acute adrenocortical stimulation by recombinant gamma interferon in human controls. Life Sciences 42 1-5.
30. Horvath CM, Wen Z & Darnell JE Jr 1995 A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes and Development 9 984-994.
31. Ikeda H, Old LJ & Schreiber RD 2002 The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine and Growth Factor Reviews 13 95-109.
32. Karalis KP, Venihaki M, Zhao J, van Vlerken LE & Chandras C 2004 NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. Journal of Biological Chemistry 279 10837-10840.
33. Katahira M, Iwasaki Y, Aoki Y, Oiso Y & Saito H 1998 Cytokine regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. Endocrinology 139 2414-2422.
34. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F & Arzt E 2002 Activation and induction of NUR77/ NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Molecular Endocrinology 16 1638-1651.
35. Kumar CS, Muthukumaran G, Frost LJ, Noe M, Ahn YH, Mariano TM & Pestka S 1989 Molecular characterization of the murine interferon gamma receptor cDNA. Journal of Biological Chemistry 264 17939-17946.
36. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y Brue T, Enjalbert A & Drouin J 2001 A pituitary cell-restricted T box factor, Tpit, activates Pomc transcription in cooperation with Pitx homeoproteins. Cell 104 849-859.
37. Levin N, Blum M & Roberts JL 1989 Modulation of basal and corticotropin-releasing factor-stimulated proopiomelanocortin gene expression by vasopressin in rat anterior pituitary. Endocrinology 125 2957-2966.
38. Levy DE & Darnell JE Jr 2002 Stats: transcriptional control and biological impact. Nature Reviews. Molecular Cell Biology 3 651-662.
39. Liu B, Mortrud M & Low MJ 1995 DNA elements with AT-rich core sequences direct pituitary cell-specific expression of the pro-opiomelanocortin gene in transgenic mice. Biochemical Journal 312 827-832.
40. Lundblad JR & Roberts JL 1988 Regulation of proopiomelanocortin gene expression in pituitary. Endocrine Reviews 9 135-158.
41. Maira M, Martens C, Philips A & Drouin J 1999 Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Molecular and Cellular Biology 19 7549-7557.
42. Mandal M, Bandyopadhyay D, Goepfert TM & Kumar R 1998 Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 16 217-225.
43. Marks-Konczalik J, Chu SC & Moss J 1998 Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. Journal of Biological Chemistry 273 22201-22208.
44. Murphy EP & Conneely OM 1997 Neuroendocrine regulation of the hypothalamic-pituitary-adrenal aids by the nurr1/nur77 subfamily of nuclear receptors. Molecular Endocrinology 11 39-47.
45. Mynard V, Guignat L, Devin-Leclerc J, Bertagna X & Catelli MG 2002 Different mechanisms for leukemia inhibitory factor-dependent activation of two proopiomelanocortin promoter regions. Endocrinology 143 3916-3924.
46. Mynard V, Latchoumanin O, Guignat L, Devin-Leclerc J, Bertagna X, Barre B, Fagart J, Coqueret O & Catelli MG 2004 Synergistic signaling by corticotropin-releasing hormone and leukemia inhibitory factor bridged by phosphorylated 3′,5′-cyclic adenosine monophosphate response element binding protein at the Nur response element (NurRE)-signal transducers and activators of transcription (STAT) element of the proopiomelanocortin promoter. Molecular Endocrinology 18 2997-3010.
47. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M & Hirano T 1996 A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO Journal 15 3651-3658.
48. Nudi M, Ouimette JF & Drouin J 2005 Bone morphogenic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity. Molecular Endocrinology 19 1329-1342.
49. Paez-Pereda M, Ledda MF, Goldberg V, Chervin A, Carrizo G, Molina H, Muller A, Renner U, Podhajcer O, Arzt E et al. 2000 High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. Journal of Clinical Endocrinology and Metabolism 85 263-269.
50. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C et al. 2001 Retinoic acid prevents experimental Cushing syndrome. Journal of Clinical Investigation 108 1123-1131.
51. Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P & Drouin J 1997a Novel dimeric NUR77 signaling mechanism in endocrine and lymphoid cells. Molecular and Cellular Biology 17 5946-5951.
52. Philips A, Maira M, Mullick A, Chamberland M, Lesage S, Hugo P & Drouin J 1997b Antagonism between NUR77 and glucocorticoid receptor for control of transcription. Molecular and Cellular Biology 17 5952-5959.
53. Pitossi F, del Rey A, Kabiersch A & Besedovsky H 1997 Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. Journal of Neuroscience Research 48 287-298.
54. Platanias LC 2005 Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews. Immunology 5 375-386.
55. Qing Y & Stark GR 2004 Alternative activation of STAT1 and STAT3 in response to interferon-gamma. Journal of Biological Chemistry 279 41679-41685.
56. Ramana CV, Gil MP, Schreiber RD & Stark GR 2002 Stat1-dependent and - independent pathways in IFN-gamma-dependent signaling. Trends in Immunology 23 96-101.
57. Ray D & Melmed S 1997 Pituitary cytokine and growth factor expression and action. Endocrine Reviews 18 206-228.
58. Saiki I, Sato K, Yoo YC, Murata J, Yoneda J, Kiso M, Hasegawa A & Azuma I 1992 Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). International Journal of Cancer 51 641-645.
59. Schindler C & Darnell JE Jr 1995 Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annual Review of Biochemistry 64 621-651.
60. Schindler CW 2002 Series introduction. JAK-STAT signaling in human disease. Journal of Clinical Investigation 109 1133-1137.
61. Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB & Rosen J 1995 Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. PNAS 92 3041-3045.
62. Sizemore N, Agarwal A, Das K, Lerner N, Sulak M, Rani S, Ransohoff R, Shultz D & Stark GR 2004 Inhibitor of kappaB kinase is required to activate a subset of interferon gamma-stimulated genes. PNAS 101 7994-7998.
63. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA et al. 1997 A family of cytokine-inducible inhibitors of signalling. Nature 387 917-921.
64. Suk K, Chang I, Kim YH, Kim S, Kim JY, Kim H & Lee NIS 2001 Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. Journal of Biological Chemistry 276 13153-13159.
65. Utsuyama M & Hirokawa K 2002 Differential expression of various cytokine receptors in the brain after stimulation with LPS in young and old mice. Experimental Gerontology 37 411-420.
66. Vankelecom H, Carmeliet P, Heremans H, Van Damme J, Dijkmans R, Billiau A & Denef C 1990 Interferon-gamma inhibits stimulated adrenocorticotropin, prolactin, and growth hormone secretion in normal rat anterior pituitary cell cultures. Endocrinology 126 2919-2926.
67. Vankelecom H, Andries M, Billiau A & Denef C 1992 Evidence that folliculostellate cells mediate the inhibitory effect of interferon-gamma on hormone secretion in rat anterior pituitary cell cultures. Endocrinology 130 3537-3546.
68. Wall L, Burke F, Smyth JF & Balkwill F 2003 The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecologic Oncology 88 S149-S151.
69. Wen Z, Zhong Z & Darnell JE Jr 1995 Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 241-250.
70. Wu AJ, Chen ZJ, Tsokos M, O'Connell BC, Ambudkar IS & Baum BJ 1996 Interferon-gamma induced cell death in a cultured human salivary gland cell line. Journal of Cellular Physiology 167 297-304.
71. Yamaguchi M, Koike K, Matsuzaki N, Yoshimoto Y, Taniguchi T, Miyake A & Tanizawa O 1991 The interferon family stimulates the secretions of prolactin and interleukin-6 by the pituitary gland in vitro. Journal of Endocrinological Investigation 14 457-461.
72. Zhong Z, Wen Z & Darnell JE Jr 1994 Stat3 and Stat4: members of the family of signal transducers and activators of transcription. PNAS 91 4806-4810.